Vincerx Pharma, Inc. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances
Vincerx Pharma, Inc. reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances of $2.50 million for the 9-month period ending 2021-09-30, per its 10-Q filed 2021-11-12.
Discontinued › Notes › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues · last filed 2021-11-12
- Vincerx Pharma, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, issuances for the quarter ending 2021-09-30 was $0.00.
- Vincerx Pharma, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, issuances for the quarter ending 2021-06-30 was $768.00K.
- Vincerx Pharma, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, issuances for the quarter ending 2021-03-31 was $1.74M.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances 9 month |
|---|---|---|---|
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $768.00K derived: sum of 2 quarters · filed 2021-11-12 | $2.50M 10-Q · filed 2021-11-12 |
| 2021-06-30 | $768.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $2.50M 10-Q · filed 2021-08-12 | |
| 2021-03-31 | $1.74M 10-Q · filed 2021-05-17 |